000			a
999			_c11131 _d11131
003			OSt
005			20200210103346.0
008			200210b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_912039 _aGeorgiev, Kaloyan
245			_aPOTENTIAL DRUG-DRUG INTERACTIONS IN HEART FAILURE P ATIENTS
250			_aVol.11(9)
260			_aM P _bInnovare Academic Sciences Pvt Ltd _c2019
300			_a37-41p.
520			_aObjective: The aim of the present study was to assess the prev alence, risk rating and the severity of hazardous p DDIs (potential drug-drug interactions) in the prescribed pharmacotherapy in the hospital discharged heart failure (HF) patients, primarily with co-administered drugs with narrow therapeutic index (statins, anticoagulants, antithrombotic drugs). Methods: The prescriptions of chronic heart failure patients for one year (January-December 2014) were analyzed for pDDIs through Lexi-interact ® software. DDIs belonging to the categories D (Consi der therapy modification) and X (Avoid combination) and/or severity of drug interaction-major, were selected for the study. Results: After reviewing the medical records of 985 patients , 239 patients were selected based on the criteria mentioned above. The average number of prescription drugs at hospital discharge was 7.27 medications (±1.84 SD) per patient. The to tal number of pDDIs was 1483 or approximately 6.2 (±3.89 SD) pDDIs per patient. Wit h respect to the risk rating, in categories D and X were detected 76 (5.12 %) and 2 (0.13 %) pDDI, respectively. The major pDDIs were 108 (7.28 %). Conclusion: HF patients are at high risk of pDDIs. Screening of prescriptions for pDDIs and monitoring of pharmacot herapy in terms of response and associated adverse drug events will contribute to patient safety.
650		0	_94639 _aPHARMACEUTICS
700			_912040 _aHvarchanova, Nadezhda
773	0		_x2656-0097 _dBhopal Innovare Academic Sciences Pvt Ltd _tInternational journal of pharmacy and pharmaceutical science
856			_uhttps://innovareacademics.in/journals/index.php/ijpps/article/view/33585/20638 _yClick here
942			_2ddc _cAR